Colorectal Cancer (CRC) Therapeutics

SUMMARY

Abstract

This report analyzes the worldwide markets for Colorectal Cancer Therapeutics in US$ Million. The major product segments analyzed are Cytotoxic Therapies (5-FU (Fluorouracil), Camptosar (Irinotecan), Eloxatin (Oxaliplatin), and Xeloda (Capecitabine), Targeted Therapies (Avastin (bevacizumab), and Erbitux (cetuximab). The report provides separate comprehensive analytics for the United States and Rest of World. Annual forecasts are provided for the period of 2001 through 2010. The report profiles 69 companies including many key and niche players worldwide such as Amgen Inc., Bristol-Myers Squibb, F.Hoffmann-La Roche Ltd., Genentech, Inc., Imclone Systems Inc., Novartis AG, Oxford Biomedica, Pfizer Inc., Sanofi-Aventis, and Schering AG. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

TABLE OF CONTENTS

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability And Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions And Scope Of Study
• Cytotoxic Therapies
• Targeted Therapies

II. EXECUTIVE SUMMARY

1. Industry Overview

• A Curtain Raiser
• Table 1: New Cases of Colorectal Cancer Diagnosed in the US for 2003-2006 (includes corresponding Graph/Chart)
• Table 2: Mortality Due to Colorectal Cancer in North America (2000-2003)-Breakdown by Region-United States, Canada and Mexico (includes corresponding Graph/Chart)
• Table 3: Mortality Due to Colorectal Cancer in Latin America (2000-2003)-Breakdown by Region-Brazil, Argentina, Venezuela, Peru, and Chile (includes corresponding Graph/Chart)
• Table 4: Mortality Due to Colorectal Cancer in Asia-Pacific (2000-2003)-Breakdown by Region-China, Japan, India, Indonesia, Philippines, Australia, Thailand, South Korea, Malaysia, Hong Kong, New Zealand, Singapore and Taiwan (includes corresponding Graph/Chart)
• Table 5: Mortality Due to Colorectal Cancer in Western Europe (2000-2003)-Breakdown by Region-Belgium, Austria, Denmark and Finland (includes corresponding Graph/Chart)
• Table 6: Staged Incidence of Cancer in the US by Race/Ethnicity: (1992-2000) (includes corresponding Graph/Chart)
• Why Screening Rate is Low in Colorectal Cancer?
• Strategies to Increase Screening Rate
• Early Screening & Detection- A Antidotes to Beat the Odds
• Test at Home
• Breakdown of Colorectal Cancer Cases Based on the Risk Category
• Guidelines for Screening & Surveillance For Early Detection of Colorectal Cancer
• Who is at a Greater Risk of Developing Colorectal Cancer?
• Genetic Disposition
• Table 7: Selected Risk Factors and their Relative Risk Percentage in Colorectal Cancer (includes corresponding Graph/Chart)
• Happy Days are Here Again
• Table 8: Five Year Disease -Free Survival Rate of Various Cancers by Type- Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, and Malignant Melanoma (includes corresponding Graph/Chart)
• An Insight into Colorectal Cancer Therapeutic Alternatives

2. Market Pulse

• Is Huge Cost of Drugs a Major Concern?
• Price Comparisons Among Leading Cancer Drugs Currently Available
• Is Cytotoxic Therapy Heading Towards the Sunset?
• An Insight into Cytotoxic Drugs Available in the US Colorectal Cancer Market
• Expiry Period of Leading Cytotoxic Drugs- Camptosar, Eloxatin, and Xeloda
• 5-FU Struggling to Hold Share
• Xeloda on a Rise with Growing Indications
• Ongoing Phase III Clinical Trials to Evaluate Efficacy of Xeloda in Colorectal Cancer
• Edotecarin-An Evolving Cytotoxic Therapy
• Targeted Therapies-All Set to Stake a Claim Over the Future
• Avastin- The Wonder Drug
• Table 9: Key Parameters that Promote use of Avastin (includes corresponding Graph/Chart)
• PTK787 (vatalanib)
• ABX-EGF
• Targeted Therapies Add Value to Treatment Strategies
• Panitumumab- A Key Contender to Erbitux
• PTK787 v/s Avastin- Serious Warfare
• Combination Therapy- Offering a Lucrative Option
• A Peek into Standard Combination Therapies in Colorectal Cancer and their Status
• Reoccurrence of Cancer -A Prime Concern
• Table 10: Revenues from Adjuvant Colorectal Cancer Therapies in the US 2004-2007 (In US$ Million) (includes corresponding Graph/Chart)
• Table 11: Number of Colorectal Cancer Patients in Adjuvant Settings in the US: 2001-2007 (includes corresponding Graph/Chart)
• Adjuvant Therapy in Colon Cancer
• Adjuvant Therapy in Rectal Cancer
• Colorectal Cancer Drugs in Adjuvant Settings

3. Clinical Trials

• Prominent Products Still in Pipeline
• A Snapshot of Potential Drugs in the Pipeline

4. Clinical Studies

• Adapalene (CD271) Retinoid Agent Induces Apoptosis in Colon Cancer Cells
• Laparoscopic Surgery Vs Open Surgery
• Discontinuation of Chemotherapy Drugs Raises the Chances of Reoccurrence
• Colorectal Cancer and Natural Substances
• Magnesium
• Vitamin D Protects Development of Tumor in Colon
• High Intake of Vitamin B Reduces Risk in Women
• Diet Rich in Flavonoids Fights Well Against Colorectal Cancer
• Colorectal Cancer and Other Medications
• NSAIDs Reduce the Risk of Colorectal Cancer
• Efficacy of Cancer Vaccine, ALVAC-CEA/B7.1, in Colorectal Cancer
• Insulin Therapy in type 2 Diabetic Patients Increases Risk

5. Product Overview

• Colorectal Cancer-An Insight
• Colorectal Cancer.... What is it....!!!
• What are the Symptoms?
• Risk Factors
• Selected General Risk Factors and their Relative Risk Rate in Colorectal Cancer
• Screening and Treatment
• Screening Options
• Digital Rectal Examination (DRE)
• Fecal Occult Blood Test
• Flexible Sigmoidoscopy
• Barium Enema
• Colonoscopy
• Additional Screening Options Of Recent Origin
• DNA-based Stool Test
• Virtual Colonoscopy
• A Comparative Analysis of Various Colorectal Cancer Screening Options Based on Parameters Such as Complexity, Risk Element, Potential Effectiveness, Overall Performance and Significant Limitations
• Appropriate Time Frame for Screening and Surveillance of Colorectal Cancer for Both Women and Men in the Age Group of 50 or More
• Supportive Diagnostic Tests
• Diagnosis/Treatment Options
• Partial Colectomy
• Chemotherapy
• Surgery
• Radiation Therapy
• A Structural Analysis of Available Treatment Options in Colorectal Cancer
• Staging
• Colorectal Cancer Therapies-At a Glance
• Cytotoxic Therapies

5-FU (Fluorouracil)

• Camptosar (Irinotecan)
• Eloxatin (Oxaliplatin)
• Xeloda (Capecitabine)
• Targeted Therapies
• Angiogenesis Pathway
• Avastin (bevacizumab)
• EGF Pathway
• Erbitux (cetuximab)
• Cell Proliferation/Apoptosis
• Immune Response
• Cancer Vaccines
• Monoclonal Antibodies & their Function
• An Insight into the Targeted Therapies
• A Synoptic Review of Available Drugs Indicated in Treating Colorectal Cancer

6. Product Approvals /Launches

• Chugai Applies for Quick Approval of Avastin in Japan
• Genentech Obtains FDA Approval for Avastin in Combination Therapy
• US FDA Approves Adjuvant Status for Roche's Oral Xeloda
• Antisoma's AS 1404 and Avastin Combination Therapy Proves Effective in Colon and Lung Cancer
• ImClone Systems and Bristol-Myers Squibb Receive Approval for Erbitux® Injection
• John Hopkins Develops Colorectal Cancer Blood Test Jointly with Howard Hughes Medical Institute and Indivumed
• Genentech Receives FDA Approval for Avastin
• Oxford BioMedica Gains Approval for Phase II
• Trial of TroVax®
• Roche's Xeloda Gets Clearance as First-Line Colorectal Cancer Treatment
• LabCorp Introduces DNA-based Colorectal Cancer Test

7. Recent Industry Activity

• Amgen Acquires Abgenix
• Chiron Merges with Novartis
• Bayer to Acquire Schering AG
• Biosite Collaborates with Oxford Genome
• Medarex Collaborates with Oxford Genome Sciences
• Pharmexa Acquires GemVax
• AstraZeneca to Acquire KuDOS Pharmaceuticals
• Aphton Corporation Acquires Igeneon
• IDM S.A. and Epimmune Merge to Form IDM Pharma
• Hybridon Renamed as Idera Pharmaceuticals
• Merck KGaA Acquires Rights for Taiho Pharmaceutical's UFT
• Novartis and Schering Co-Promote PTK787/ZK 222584 Cancer Drug
• TWTI and Genzyme Genetics Set Up a Marketing Association
• Callisto Receives Patent for its Colon Cancer Drug
• Amgen and Abgenix Receive FDA Approval for Panitumumab in Metastatic Colorectal Cancer
• ADVENTRX Receives MHRA Approval to Initiate Phase IIb Clinical Trial
• Sanofi Acquires Aventis to Form Sanofi-Aventis

8. Focus on Select Players

• Amgen Inc. (USA)
• Bristol-Myers Squibb (USA)
• F.Hoffmann-La Roche Ltd. (Switzerland)
• Genentech, Inc. (USA)
• Imclone Systems Inc. (USA)
• Novartis AG (Switzerland)
• Oxford Biomedica (UK)
• Pfizer Inc. (USA)
• Sanofi-Aventis (France)
• Schering AG (Germany)

9. Global Market Perspective

• Table 12: World Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Geographic Region/Country - United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 13: World 10-Year Perspective for Colorectal Cancer Therapies by Geographic Region/Country - Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2001, 2006 and 2010
• Table 14: World Recent Past, Current & Future Analysis for Cytotoxic Therapies for Colorectal Cancer by Geographic Region/Country - United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 15: World 10-Year Perspective for Cytotoxic Therapies for Colorectal Cancer by Geographic Region/Country - Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2001, 2006 and 2010
• Table 16: World Recent Past, Current & Future Analysis for Camptosar in Colorectal Cancer by Geographic Region/Country - United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 17: World 10-Year Perspective for Camptosar in Colorectal Cancer by Geographic Region/Country - Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2001, 2006 and 2010
• Table 18: World Recent Past, Current & Future Analysis for Eloxatin in Colorectal Cancer by Geographic Region/Country - United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 19: World 10-Year Perspective for Eloxatin in Colorectal Cancer by Geographic Region/Country - Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2001, 2006 and 2010
• Table 20: World Recent Past, Current & Future Analysis for Xeloda in Colorectal Cancer by Geographic Region/Country - United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding graph/chart)
• Table 21: World 10-Year Perspective for Xeloda in Colorectal Cancer by Geographic Region/Country - Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2001, 2006 and 2010
• Table 22: World Recent Past, Current & Future Analysis for Targeted Therapies for Colorectal Cancer by Geographic Region/Country - United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2010 (includes corresponding graph/chart)
• Table 23: World 6-Year Perspective for Targeted Therapies for Colorectal Cancer by Geographic Region/Country - Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2004, 2006 and 2010
• Table 24: World Recent Past, Current & Future Analysis for Avastin in Colorectal Cancer by Geographic Region/Country - United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2010 (includes corresponding graph/chart)
• Table 25: World 6-Year Perspective for Avastin in Colorectal Cancer by Geographic Region/Country - Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2004, 2006 and 2010
• Table 26: World Recent Past, Current & Future Analysis for Erbitux in Colorectal Cancer by Geographic Region/Country - United States and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2010 (includes corresponding graph/chart)
• Table 27: World 6-Year Perspective for Erbitux in Colorectal Cancer by Geographic Region/Country - Percentage Breakdown of Dollar Sales for United States and Rest of World for Years 2004, 2006 and 2010

III. MARKET

1. US

• A. Market Analysis
• Introduction
• Market Accelerators
• Market Challenges
• Market Inhibitors
• Why Cost of Cancer Drugs is Too High in the US?
• Free-market Healthcare System- "For" & "Against"
• Erbitux- Making a Way Through the Colorectal Cancer Market
• Erbitux-A Blockbuster Drug in Third-Line Therapy
• Erbitux Enters the Genre of Second-Line Therapies
• Who Leads the Pack?
• Sanofi-Aventis- The Clear Leader
• Table 28: US Colorectal Cancer Market (2004): Percentage Breakdown of Leading Players-Sanofi-Aventis, Genentech, Pfizer, ImClone Systems/Bristol Myers-Squibb, Roche, and Generic Manufacturers-Ranked by Revenue (includes corresponding Graph/Chart)
• Table 29: US Colorectal Cancer Market for Cytotoxic Therapies (2004): Percentage Breakdown of Leading Players-Sanofi-Aventis, Pfizer, Roche and Generic Manufacturers-Ranked by Revenue (includes corresponding Graph/Chart)
• Table 30: US Colorectal Cancer Market for Targeted Therapies (2004): Percentage Breakdown of Leading Players-Genentech and ImClone Systems/Bristol Myers-Squibb-Ranked by Revenues
• Crucial Statistics
• Table 31: Incidence of Colorectal Cancer in the US (2006)-Breakdown by Stages (includes corresponding Graph/Chart)
• Table 32: US Colorectal Cancer Statistics for 2004 & 2003 (includes corresponding Graph/Chart)
• Table 33: New Cases of Colorectal Cancer in the US for the years 2005 & 2006-Breakdown by Cancer Type
• Table 34: New Colorectal Cancer Cases in the US in 2004 & 2003-Breakdown by Type & Gender
• Product Approvals/Launches
• Strategic Developments
• Focus on Select Players
• B. Market Analytics
• Table 35: US Recent Past, Current & Future Analysis For Colorectal Cancer Therapeutics By Product Segments- Cytotoxic Therapies (5-Fu, Camptosar, Eloxatin And Xeloda) And Targeted Therapies (Avastin And Erbitux) Markets Independently Analyzed With Annual Sales In Us$ Million For Years 2001 Through 2010 (includes corresponding Graph/Chart)
• Table 36: US 10-Year Perspective For Colorectal Cancer Therapeutics By Product Segments - Percentage Breakdown Of Dollar Sales For Cytotoxic Therapies (5-Fu, Camptosar, Eloxatin And Xeloda) And Targeted Therapies (Avastin And Erbitux) For Years 2001, 2006 And 2010 (includes corresponding Graph/Chart)

2. Rest of World

• A. Market Analysis
• Focus on Select Countries
• Canada
• Incidence
• Vital Statistics
• Table 37: Canadian Cancer Market (2005): Percentage Breakdown of New Cancer Cases Among Men (includes corresponding Graph/Chart)
• Table 38: Canadian Cancer Market (2005): Percentage Breakdown of Cancer Mortality Among Men (includes corresponding Graph/Chart)
• Table 39: Canadian Cancer Market (2005): Percentage Breakdown of New Cancer Cases Among Women (includes corresponding Graph/Chart)
• Table 40: Canadian Cancer Market (2005): Percentage Breakdown of Cancer Mortality Among Women (includes corresponding Graph/Chart)
• Table 41: New Colorectal Cancer Cases in Canada in 2005- By Gender
• Table 42: New Colorectal Cancer Cases in Canada in 2005-Breakdown By Age Group (includes corresponding Graph/Chart)
• Table 43: Colorectal Cancer Mortality Statistics in Canada in 2005-Ranked By Gender
• Table 44: Colorectal Cancer Mortality Statistics in Canada in 2005-Breakdown By Age Group (includes corresponding Graph/Chart)
• Table 45: Incidence of Colorectal Cancer Among Men in Canada-By Region: 2005 (includes corresponding Graph/Chart)
• Table 46: Incidence of Colorectal Cancer Among Women in Canada-By Region: 2005 (includes corresponding Graph/Chart)
• Finland
• Overview
• Active Screening Programs- A Mission to Fight Against Cancer
• Product Approvals
• Strategic Developments
• Focus on Select Players
• B. Market Analytics
• Table 47: Rest of World Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Product Segments- Cytotoxic Therapies (Camptosar, Eloxatin and Xeloda) and Targeted Therapies (Avastin and Erbitux) Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 48: Rest of World 10-Year Perspective for Colorectal Cancer Therapeutics by Product Segments - Percentage Breakdown of Dollar Sales for Cytotoxic Therapies (Camptosar, Eloxatin and Xeloda) and Targeted Therapies (Avastin and Erbitux) for Years 2001, 2006 and 2010 (includes corresponding Graph/Chart)

IV. COMPETITION

• 1. Abbott Laboratories (USA)
• Table 49: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 50: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 51: Half Yearly Sales Analysis by Business Segment: 2005-2006 (H1) (In US$ million)
• Table 52: Annual Sales Analysis: 2003-2005 (In US$ million)
• Table 53: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• Table 54: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ million)
• Table 55: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 2. Adherex Technologies, Inc. (USA)
• 3. Adventrx Pharmaceuticals, Inc. (USA)
• 4. Amgen, Inc. (USA)
• Table 56: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 57: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million)
• Table 58: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 59: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
• Table 60: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 5. AnorMed, Inc. (Canada)
• Table 61: Annual Sales Analysis: 2004-2006 (In Can$ million)
• 6. Antigenics, Inc. (USA)
• Table 62: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 63: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 64: Annual Sales Analysis: 2003-2005 (In US$ million)
• 7. Aphton Corporation (USA)
• 8. Arius Research, Inc. (Canada)
• Table 65: Annual Sales Analysis: 2004-2005 (In Can$ million)
• 9. Astellas Pharma US, Inc. (USA)
• 10. Astrazeneca PLC (UK)
• Table 66: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 67: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 68: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ million)
• Table 69: Annual Sales Analysis: 2003-2005 (In US$ million)
• Table 70: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• Table 71: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 11. Avastin (USA)
• 12. AVI Biopharma, Inc. (USA)
• Table 72: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ thousands)
• Table 73: Half Yearly Sales Analysis by Quarter: 2005-2006 (In US$ thousands)
• Table 74: Annual Sales Analysis: 2003-2005 (In US$ thousands)
• Table 75: Quarterly Sales Analysis: 2004-2005 (In US$ thousands)
• 13. Bayer HealthCare AG (Germany)
• Table 76: Annual Sales Analysis: 2004-2005 (In € million)
• Table 77: Annual Sales Analysis by Business Segment: 2004-2005 (In € million)
• Table 78: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million)
• 14. Biomira, Inc. (Canada)
• 15. Biosite, Inc. (USA)
• Table 79: First Quarter Sales Analysis: 2005-2006 (In US$ million)
• Table 80: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 81: Quarterly Sales Analysis: 2004-2005 (In US$ million)
• 16. BioStratum, Inc. (USA)
• 17. Boehringer Ingelheim GmbH (Germany)
• Boehringer Ingelheim Corporation (USA)
• 18. Bristol-Myers Squibb Company (USA)
• Table 82: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion)
• Table 83: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ billion)
• Table 84: Half Yearly Sales Analysis by Business Segment: 2005-2006 (H1) (In US$ billion)
• Table 85: Annual Sales Analysis: 2003-2005 (In US$ billion)
• Table 86: Annual Sales Analysis by Quarter: 2004-2005 (In US$ billion)
• Table 87: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ billion)
• Table 88: Annual Sales Analysis by GeographicRegion: 2004-2005 (In US$ billion)
• 19. Callisto Pharmaceuticals, Inc. (USA)
• 20. ChemGenex Pharmaceuticals Ltd. (Australia)
• Table 89: Annual Sales Analysis: 2004-2005 (In US$ thousands)
• 21. Dendreon Corporation (USA)
• Table 90: First Quarter Sales Analysis: 2005-2006 (In US$ million)
• Table 91: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 92: Quarterly Sales Analysis: 2004-2005 (In US$ million)
• Eisai, Inc. (USA)
• 22. Eli Lilly & Company (USA)
• Table 93: Annual Sales Analysis: 2003-2005 (In US$ million)
• 23. F. Hoffmann-La Roche Ltd. (Switzerland)
• Table 94: First Quarter Sales Analysis: 2005-2006 (In CHF billion)
• Table 95: First Quarter Sales Analysis by Segment: 2005-2006 (In CHF billion)
• Table 96: Annual Sales Analysis: 2003-2005 (In CHF billion)
• Roche Laboratories, Inc. (USA)
• Chugai Pharmaceutical Co., Ltd. (Japan)
• Table 97: First Quarter Sales Analysis: 2005-2006 (In \ million)
• Table 98: Annual Sales Analysis: 2004-2005 (In \ million)
• 24. Gemin X Biotechnologies, Inc. (Canada)
• 25. Genentech, Inc. (USA)
• Table 99: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 100: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 101: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 26. Genvec, Inc. (USA)
• Table 102: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 103: Annual Sales Analysis: 2004-2005 (In US$ million)
• 27. Genzyme Corporation (USA)
• Table 104: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 105: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 106: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million)
• Table 107: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 108: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• Table 109: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
• Table 110: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion)
• 28. Glaxosmithkline PLC (UK)
• Table 111: Half Yearly Sales Analysis: 2005-2006 (H1) (In £ million)
• Table 112: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In £ million)
• Table 113: Annual Sales Analysis: 2004-2005 (In £ million)
• Table 114: Annual Sales Analysis by Segment: 2004-2005 (In £ million)
• GlaxoSmithKline, Inc. (USA)
• 29. Glycogenesys, Inc. (USA)
• 30. Idera Pharmaceuticals, Inc. (USA)
• 31. IDM Pharma, Inc. (USA)
• Table 115: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 116: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 117: Annual Sales Analysis: 2004-2005 (In US$ million)
• 32. ImClone Systems, Inc. (USA)
• Table 118: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 119: Annual Sales Analysis: 2003-2005 (In US$ million)
• Table 120: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 33. Immunomedics, Inc. (USA)
• Table 121: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ million)
• Table 122: Nine Months Sales Analysis by Geographic Region: 2005-2006 (Nine Months Ended, March) (In US$ million)
• Table 123: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 124: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 34. Indivumed GmbH (Germany)
• 35. Intracel (USA)
• 36. Introgen Therapeutics, Inc. (USA)
• Table 125: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 126: Annual Sales Analysis: 2003-2005 (In US$ million)
• 37. Ivax Corporation (USA)
• Table 127: Nine Months Sales Analysis: 2004-2005 (Nine Months Ended, September) (In US$ billion)
• Table 128: Nine Months Sales Analysis by Quarter: 2004-2005 (Nine Months Ended, September) (In US$ billion)
• Table 129: Nine Months Sales Analysis by Product: 2004-2005 (Nine Months Ended, September) (In US$ billion)
• Table 130: Nine Months Sales Analysis by Geographic Region: 2004-2005 (Nine Months Ended, September) (In US$ billion)
• 38. Johnson & Johnson Pharmaceutical Research & Development LLC (USA)
• 39. Lorus Therapeutics (Canada)
• 40. Medarex, Inc. (USA)
• Table 131: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)
• Table 132: Annual Sales Analysis: 2003-2005 (In US$ million)
• Table 133: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 41. MediGene AG (Germany)
• Table 134: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million)
• 42. Medimmune, Inc. (USA)
• Table 135: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 136: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 137: Half Yearly Sales Analysis by Operation: 2006-2005 (In US$
• Table 138: Annual Sales Analysis: 2003-2005 (In US$ million)
• Table 139: Annual Sales Analysis by Operation: 2004-2005 (In US$ million)
• Table 140: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 43. Merck & Co., Inc. (USA)
• Table 141: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 142: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 143: Half Yearly Sales Analysis by Product: 2005-2006 (H1) (In US$ million)
• Table 144: Annual Sales Analysis: 2003-2005 (In US$ million)
• Table 145: Annual Sales Analysis by Product: 2004-2005 (In US$ million)
• Table 146: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 44. Merck KGaA (Germany)
• Table 147: Annual Sales Analysis: 2004-2005 (In € million)
• Table 148: Annual Sales Analysis Segment: 2004-2005 (In € million)
• 45. Millennium Pharmaceuticals, Inc. (USA)
• Table 149: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 150: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 151: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 46. Myriad Genetics, Inc. (USA)
• Table 152: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ million)
• Table 153: Nine Months Sales Analysis by Quarter: 2005-2006 (Nine Months Ended, March) (In US$ million)
• Table 154: Nine Months Sales Analysis by Segment: 2005-2006 (Nine Months Ended, March) (In US$ million)
• Table 155: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 156: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• Table 157: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
• 47. Novartis AG (Switzerland)
• Table 158: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 159: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million)
• Table 160: Annual Sales Analysis: 2003-2005 (In US$ million)
• Table 161: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
• Table 162: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• Chiron Corporation (USA)
• Table 163: Annual Sales Analysis: 2003-2005 (In US$ million)
• Table 164: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• Table 165: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
• Table 166: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• Novartis Pharmaceuticals Corporation (USA)
• 48. Onyx Pharmaceuticals, Inc. (USA)
• Table 167: Annual Sales Analysis: 2004-2005 (In US$ million)
• 49. Ortho Biotech Products LP (USA)
• 50. OSI Pharmaceuticals (USA)
• Table 168: Half Yearly Sales Analysis: 2005-2006 (In US$ million)
• Table 169: Annual Sales Analysis: 2004-2005 (In US$ million)
• 51. Oxford Biomedica PLC (UK)
• Table 170: Annual Sales Analysis: 2004-2005 (In £ million)
• 52. Oxford Genome Sciences (U.K.) Ltd. (UK)
• 53. Oxigene, Inc. (USA)
• 54. Pfizer, Inc. (USA)
• Table 171: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion)
• Table 172: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ billion)
• Table 173: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ billion)
• Table 174: Annual Sales Analysis: 2003-2005 (In US$ billion)
• 55. Pharmexa A/S (Denmark)
• Table 175: Half Yearly Sales Analysis: 2005-2006 (H1) (In DKK million)
• 56. Sanofi-Aventis (France)
• Table 176: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million)
• Table 177: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In € million)
• Table 178: Annual Sales Analysis: 2004-2005 (In € million)
• Table 179: Annual Sales Analysis by Segment: 2004-2005 (In € million)
• Table 180: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million)
• Sanofi-Aventis (USA)
• 57. Schering AG (Germany)
• Table 181: First Quarter Sales Analysis: 2005-2006 (In € billion)
• Table 182: First Quarter Sales Analysis by Segment: 2005-2006 (In € billion)
• Table 183: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In € billion)
• Table 184: Annual Sales Analysis: 2003-2005 (In € billion)
• Table 185: Annual Sales Analysis by Segment: 2004-2005 (In € billion)
• Table 186: Annual Sales Analysis by Geographic Region: 2004-2005 (In € billion)
• Schering-Plough Corporation (USA)
• Table 187: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 188: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million)
• Table 189: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 190: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) (Germany))
• Table 191: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
• Table 192: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 58. Supergen, Inc. (USA)
• Table 193: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 194: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 195: Annual Sales Analysis: 2004-2005 (In US$ million)
• 59. Telik, Inc. (USA)
• 60. Therion Biologics Corporation (USA)
• 61. Third Wave Technologies, Inc. (USA)
• Table 196: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 197: Annual Sales Analysis: 2004-2005 (In US$ million)
• 62. Titan Pharmaceuticals, Inc. (USA)
• Table 198: Annual Sales Analysis: 2004-2005 (In US$ million)
• 63. Topotarget A/S (Denmark)
• Table 199: Annual Sales Analysis: 2004-2005 (In DKK million)
• 64. Transgene SA (France)
• Table 200: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million)
• Table 201: Annual Sales Analysis: 2004-2005 (In € million)
• 65. Viventia Biotech, Inc. (Canada)
• 66. Wyeth (USA)
• Table 202: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion)
• Table 203: Half Yearly Sales Analysis by Segment: 2006-2005 (H1) (In US$ billion)
• Table 204: Annual Sales Analysis: 2004-2005 (In US$ billion)
• Table 205: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion)
• Table 206: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion)
• 67. Xoma (US) LLC (USA)
• Table 207: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 208: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 209: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 68. YM Biosciences, Inc. (Canada)
• Table 210: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In Can$ million)
• Table 211: Annual Sales Analysis: 2004-2005 (In Can$ million)